{"entity":{"id":"nct07158918","kind":"trial","name":"ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by ABL Bio, Inc., now recruiting.","summary":"ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07158918 by ABL Bio, Inc., with 65 participants planned, started 2025-08-06 and due to reach its primary completion in 2027-12-02. Interventions recorded: ABL103, KEYTRUDA® (pembrolizumab) and Taxane.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07158918","url":"https://clinicaltrials.gov/study/NCT07158918"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07158918","phase":"1/2","setting":"A Multicenter, Open-label, Phase 1b/2 Trial of ABL103, a Bispecific Antibody of B7-H4 and 4-1BB, in Combination With Pembrolizumab With/Without Taxane in Subjects With Selected, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors","sponsor":"ABL Bio, Inc.","enrolled":65,"outcomes":[]},"route":"/trials/nct07158918/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}